Mark Wilson¹*, Anna Topping¹, Stephan Praet²

¹Sports Medicine, Australian Institute of Sport, Bruce ACT, Australia
²Ochre Health Medical Centre, Health Hub, Bruce ACT, Australia

*Corresponding Author: Mark Wilson, Australasian College of Sport and Exercise Physicians, Australia.

Received: June 15, 2022; Published: September 28, 2022

Abstract

Introduction: Prolotherapy is an injection-based therapy used for multiple acute and chronic musculoskeletal pain drivers. The aim of this clinical discussion is to review the clinical considerations in the use of prolotherapy in sport and exercise medicine. We will also compare intervention options and provide valuable clinical pearls.

Methodology: The focus of this clinical discussion is on the application of prolotherapy in clinical practice.

Summary: it is hoped that this narrative review guides clinicians on possible uses of prolotherapy in clinical practice, based on the current evidence of efficacy, complications and risk profile. The integration of clinical experience, combined with a review of the best evidence in the field, may assist in clinical decision making.

Keywords: Dextrose; Prolotherapy; proliferant

References

1. Hackett GS. “Joint stabilization through induced ligament sclerosis”. Ohio State College of Medicine Journal 49 (1953): 877-884.
2. Hackett GS., et al. “Ligament and Tendon Relaxation Treated by Prolotherapy”. Oak Park: Gustav A. Hemwall (1993).
3. Hackett GS and Huang TC. “Prolotherapy for sciatica from weak pelvic ligaments and bone dystrophy”. Clinical Medicine (Northfield Il) 8 (1961): 2301-2316.
4. Andriachi T., et al. “Ligament: injury and repair”. In: Injury and Repair of the Musculoskeletal Soft Tissues, edited by Woo SY, Buckwalter JA. Park Ridge, IL: AAOS (1987).
5. Frank CB., et al. “Normal ligament properties and ligament healing”. Clinical Orthopaedics and Related Research (1985): 15-25.
6. Stecco C., et al. “The fascia: the forgotten structure”. Italian Journal of Anatomy and Embryology3 (2011): 127.
7. Findley T., et al. “Fascia research–a narrative review”. Journal of Bodywork and Movement Therapies 1 (2012): 67-75.
8. Stecco C and Schleip R. “A fascia and the fascial system”. Journal of Bodywork and Movement Therapies 1 (2016): 139-140.
9. Stecco C., et al. “Hyaluronan within fascia in the aetiology of myofascial pain”. Surgical and Radiologic Anatomy10 (2011): 891-896.
10. Dean Reeves K., et al. “Short Term Analgesic Effects of 5% Dextrose Epidural Injections for Chronic Low Back Pain: A Randomized Controlled Trial”.  Anesthesia and Pain Medicine1 (2016): e42550.
11. Fullerton BD. “Prolotherapy for the Thoracolumbar Myofascial System”. Physical Medicine and Rehabilitation Clinics of North America1 (2018): 125-138.
12. Linetsky FS., et al. “Pain management with regenerative injection therapy (RIT)”. In: Weiner RS, ed. Pain Management. Boca Raton, FL: CRC Press (2002): 381-402.
13. Reeves KD and Hassanein K. “Randomized prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without ACL laxity”. Alternative Therapies in Health and Medicine2 (2000): 68-80.
14. Topol GA., et al. “Efficacy of dextrose prolotherapy in elite male kicking-sport athletes with chronic groin pain”. Archives of Physical Medicine and Rehabilitation4 (2005): 697-702.
15. Kim E and Lee JH. “Autologous platelet-rich plasma versus dextrose prolotherapy for the treatment of chronic recalcitrant plantar fasciitis”. PM and R 2 (2014): 152-158.
16. Schleip R., et al. “Fascia is able to contract in a smooth muscle-like manner and thereby influence musculoskeletal mechanics”. Journal of Biomechanics1 (2006): S488.
17. Krieg T., et al. “Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions”. Arthritis Research and Therapy2 (2007): S4.
18. Schleip R., et al. “Active fascial contractility: fascia may be able to contract in a smooth muscle-like manner and thereby influence musculoskeletal dynamics”. Medical Hypotheses2 (2005): 273-277.
19. Pipelzadeh MH and Naylor IL. “The in vitro enhancement of rat myofibroblast contractility by alterations to the pH of the physiological solution”. European Journal of Pharmacology2-3 (1998): 257-259.
20. Klingler W., et al. “Clinical relevance of fascial tissue and dysfunctions”. Current Pain and Headache Reports8 (2014): 439.
21. Kumka M and Bonar J. “Fascia: a morphological description and classification system based on a literature review”. The Journal of the Canadian Chiropractic Association 3 (2012): 179.
22. Li B and Wang JH. “Fibroblasts and myofibroblasts in wound healing: force generation and measurement”. Journal of Tissue Viability4 (2011): 108-120.
23. Li B and Wang JH. “Application of sensing techniques to cellular force measurement”. Sensors11 (2010): 9948-9962.
24. Grouf JL., et al. “Differential effects of EGF and TGF-β1 on fibroblast activity in fibrin-based tissue equivalents”. Tissue engineering4 (2007): 799-807.
25. Balestrini JL and Billiar KL. “Magnitude and duration of stretch modulate fibroblast remodelling”. Journal of Biomechanical Engineering5 (2009).
26. Griggs LA., et al. “Fibronectin fibrils regulate TGF-β1-induced epithelial-mesenchymal transition”. Matrix Biology 60 (2017): 157-175.
27. Trescot A. “Everything old is new again: new developments in prolotherapy”. Techniques in Regional Anaesthesia and Pain Management1-2 (2015): 14-18.
28. Kahlenberg CA., et al. “New developments in the use of biologics and other modalities in the management of lateral epicondylitis”. BioMed Research International (2015).
29. Güran Ş., et al. “Dextrose solution used for prolotherapy decreases cell viability and increases gene expressions of angiogenic and apoptotic factors”. Gulhane Medical Journal2 (2018).
30. Cusi M., et al. “The use of prolotherapy in the sacroiliac joint”. British Journal of Sport and Exercise Medicine2 (2010): 100-104.
31. Pain PL. “Prolotherapy for pelvic ligament pain: A case report”. Journal of Prolotherapy2 (2009): 89-95.
32. Wheaton MT and Jensen N. “The Ligament Injury-Osteoarthritis Connection: The Role of Prolotherapy in Ligament Repair”. Journal of Prolotherapy 4 (2011): 790-812.
33. Klein RG., et al. “Proliferant Injections for Low Back Pain:
    Histological Changes of Injected Ligaments and Objective Measurements of Lumbar Spine Mobility Before and After Treatment”. Journal of Neurological and Orthopaedic Medicine and Surgery 10 (1989): 123-126.
34. Zügel M., et al. “Fascial tissue research in Sport and Exercise medicine: from molecules to tissue adaptation, injury and diagnostics: consensus statement”. British Journal of Sports Medicine 23 (2018): 1497.
35. Ekwueme EC., et al. “Prolotherapy induces an inflammatory response in human tenocytes in vitro”. Clinical Orthopaedics and Related Research8 (2017): 2117-2127.
36. Liu YK., et al. “An in-situ study of the influence of a sclerosing solution in rabbit medical collateral ligaments and its junction strength”. Connective Tissue Research 11 (1983): 95-102.
37. Dechow E., et al. “A randomized, double-blind, placebo-controlled trial of sclerosing injections in patients with chronic low back pain”. Rheumatology (Oxford) 38 (1999): 1255-1259.
38. Yoshii Y., et al. “Effects of hypertonic dextrose injections in the rabbit carpal tunnel”. Journal of Orthopaedic Research 29 (2011): 1022-1027.
39. Wu YT., et al. “Six-month efficacy of perineural dextrose for carpal tunnel syndrome: a prospective randomized double-blind controlled trial”. Mayo Clinic Proceedings 92 (2017): 1179-1189.
40. Why W. “Neural prolotherapy”. Patients 2 (2011): 639-643.
41. Lyftogt J. “Prolotherapy and Achilles tendinopathy: a prospective pilot study of an old treatment”. Australasian Musculoskeletal Medicine 10 (2005): 16-19. 
42. M Bruce MacIver and Darryl L Tanelian. “Activation of C fibers by Metabolic Perturbations Associated with Tourniquet Ischaemia”. Anesthesiology 76 (1992): 617.
43. Lyftogt J. “Subcutaneous prolotherapy for Achilles tendinopathy: The best solution?” Australasian Musculoskeletal Medicine2 (2007): 107.
44. Reeves D and Rabago D. “Therapeutic Injection of Dextrose: Prolotherapy Perineural Injection Therapy and Hydrodissection” (2019).
45. Lam SK., et al. “Transition from deep regional blocks toward deep nerve hydrodissection in the upper body and torso: Method description and results from a retrospective chart review of the analgesic effect of 5% dextrose water as the primary hydrodissection injectate to enhance safety”. BioMed Research International (2017): 2017.
46. Dufour E., et al. “Ultrasound-guided perineural circumferential median nerve block with and without prior dextrose 5% hydrodissection: a prospective randomized double-blinded noninferiority trial”. Anesthesia and Analgesia 115 (2012): 728-733.
47. Conaway E and Browning B. “Neural prolotherapy for neuralgia”. Journal of Prolotherapy 6 (2014): e928-931.
48. Wu YT., et al. “Six-month efficacy of perineural dextrose for carpal tunnel syndrome: a prospective, randomized, double-blind, controlled trial”. In Mayo Clinic Proceedings8 (2017): 1179-1189.
49. Hauser RA., et al. “A systematic review of dextrose prolotherapy for chronic musculoskeletal pain. Clinical Medicine Insights”. Arthritis and Musculoskeletal Disorders 9 (2016): CMAMD-S39160.
50. Rabago David MD., et al. “A Systematic Review of Prolotherapy for Chronic Musculoskeletal Pain”. Clinical Journal of Sport Medicine5 (2015): E376.

Citation

Citation: Mark Wilson., et al. “Dextrose Prolotherapy - Mechanism of Action".Acta Scientific Orthopaedics 5.10 (2022): 149-156.

Copyright

Copyright: © 2022 Mark Wilson., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.